DNA Script Signs Innovation Development Contract With French Defence Innovation Agency to Enable On-Demand Diagnostics Against Emerging Biothreats
28.1.2021 09:00:00 EET | Business Wire | Press release
DNA Script, a leading pioneer in enabling DNA synthesis on demand, today announced a partnership with the French Defence Innovation Agency, in liaison with the French Armament General Directorate (DGA), to develop a prototype for rapid mobile manufacturing of DNA primers and probes, key components of detection and diagnostic tests for pathogens. The joint project will employ DNA Script’s novel enzymatic synthesis platform to quickly generate high-fidelity nucleic acids. The prototypes to be developed by DNA Script will be evaluated by the DGA. As part of the agreement, DNA Script will receive $1.6 million in funding.
In an emerging biothreat, like the ongoing COVID-19 pandemic, conventional sources of supply for key reagents (qPCR primers and probes in particular) become a limiting factor. Therefore, it is essential to enable an on-demand, agile source for custom reagent manufacturing. The DGA identified DNA Script’s SYNTAX™ platform, a benchtop instrument that synthesizes high-quality, custom nucleic acids in hours, a key capability that enables scientists to iterate faster in response to emerging biothreats, as a potential solution. The underlying core technology, enzymatic DNA synthesis, mimics the enzymatic process used by nature, thus avoiding the use of harsh organic solvents or the need to avoid the presence of air or water as required by conventional chemical approaches commercially available today.
DNA Script will adapt its SYNTAX™ platform to enable the synthesis of the DNA reagents such as Taqman probes, required in PCR-based molecular biology diagnostics. SYNTAX™ is the world’s first instrument to use an enzymatic process for nucleic acid synthesis.
“We are thrilled to collaborate with the French Ministry for Armed Forces on this important initiative to rapidly detect, characterize and mitigate threats from newly emerging or engineered pathogens,” said Thomas Ybert, Chief Executive Officer of DNA Script. “We believe that the speed, efficiency and ease of use of our SYNTAX™ nucleic acid printer and underlying enzymatic synthesis technology will be critical in addressing future pandemics.”
About DNA Script
Founded in 2014 in Paris, DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science. The company is pioneering an alternative to traditional DNA synthesis called enzymatic DNA synthesis, or EDS, making this technology accessible to labs with the world’s first benchtop enzymatic synthesis instrument, SYNTAX™. By putting DNA synthesis back in the lab, DNA Script is transforming life science research through innovative technology that gives researchers unprecedented autonomy. www.dnascript.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210127005926/en/
Contact information
Press in the US
Seismic
Eric Schubert
415-939-4366
eric@teamseismic.com
Press in Europe
ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59
caroline@alizerp.com
DNA Script
publicrelations@dnascript.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Objectway Acquires Swiss Private Banking Technology Business From FNZ to Strengthen Its Pan-European Positioning1.7.2026 14:10:00 EEST | Press release
Objectway, a global wealthtech partner for banking, wealth and asset management firms, today announced the acquisition from FNZ of their Swiss private banking technology business FNZ Switzerland SA (formerly operating as New Access). The business will now be operated under the Objectway Switzerland brand. Objectway welcomes a team of over 160 professionals, bringing their expertise and professionalism honed in developing innovative, award-winning solutions for over 40 private banks. The acquisition is a significant step in Objectway’s growth strategy, reinforcing its commitment to expanding its presence in key international wealth hubs such as Switzerland, Liechtenstein, Luxembourg, Monaco and the Bahamas, where the newly joined business already serves both domestic and international cross-border clients. The agreement further expands Objectway’s scalable core-to-digital capabilities supporting end-to-end private banking operations, while leveraging an international team and operationa
NIQ Completes Acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights Business, Expanding Digital Commerce Intelligence Capabilities1.7.2026 14:00:00 EEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that it has completed the acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights business. The acquired business operates in China under the YiMian (“一面”) brand and is a leading provider of eCommerce, social commerce, and digital shelf solutions. The acquisition expands NIQ’s capabilities across China and Southeast Asia and strengthens its ability to measure and understand consumer behavior across retail, eCommerce, social commerce, and digital environments — advancing NIQ’s mission to deliver The Full View™, the most complete understanding of consumer behavior across online and offline channels. It also enhances NIQ’s data and analytics foundation by expanding access to rich digital commerce signals that support the development of more advanced analytics and AI-powered solutions. By bringing together NIQ’s global intelligence, analytics, and retail measurement capabilities with the ac
Azalea Vision Awarded Prestigious EIC Accelerator Funding to Advance Smart Contact Lens into Clinical Development1.7.2026 14:00:00 EEST | Press release
Azalea Vision, a Belgian healthtech company building the first medical-grade smart contact lens, today announced it has been selected for the European Innovation Council (EIC) Accelerator, the European Union’s flagship program for breakthrough, market-creating deep tech. Azalea is the only Belgian company selected in this round and will receive up to €7.5 million, including a non-dilutive €2.5 million grant and a planned €5 million equity investment from the EIC Fund, to advance its medical-grade smart contact lens platform into clinical development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701144267/en/ Azalea Vision Co-founder and CTO Andrés Vásquez Quintero undergoing an on-eye evaluation of the ALMA smart contact lens. Beyond the funding, the award is a strong external endorsement of Azalea’s technology and long-term vision. Built on its proprietary smart contact lens platform, Azalea’s smart lens is designed to
Croma-Pharma Announces FDA Approval of Obagi saypha® ChIQ™ in the United States1.7.2026 13:34:00 EEST | Press release
Wrapping up the first half of 2026 with another important milestone, Croma-Pharma announces the FDA approval of Obagi saypha® ChIQ™ in the United States. Obagi saypha® ChIQ™ injectable hyaluronic acid gel is approved for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21. Developed and manufactured by Croma-Pharma and commercialized by Obagi Medical, a Waldencast company, in the U.S., ChIQ™ follows the approval of Obagi saypha® MagIQ™ in September 2025 and further broadens the availability of Croma's injectable aesthetic solutions in the United States. As demand for minimally invasive aesthetic treatments continues to grow, the approval broadens the range of treatment options available to healthcare professionals and patients seeking safe and natural-looking aesthetic outcomes. "With the approval of ChIQ™, we continue to strengthen the presence of our saypha® portfolio in the United States," said Andreas Prinz, Chief Executive Officer of Crom
Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Accelerate Global Commercial Expansion1.7.2026 13:01:00 EEST | Press release
Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dr. Hubert Scholze as Chief Business Officer (CBO), effective July 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701630118/en/ Dr. Hubert Scholze, Chief Business Officer, Rezon Bio As a member of Rezon Bio’s Executive Leadership Team, Dr. Hubert Scholze will lead the company’s commercial functions, overseeing Business Development, Market Intelligence, Global Marketing, Proposal Management and Project Management. Hubert Scholze, PhD will be responsible for Rezon Bio’s commercial strategy, strengthening strategic partnerships, supporting the company’s continued international growth, and ensuring a seamless client experience from initial engagement to program execution. His appointment comes at pivotal moment for Rezon Bio as the company continues to strengthen its integrated
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom